Header
Stroke Sciences Group
About Us
Research
Education & Training
People
Patient Care
Department of Neurology

The UCSF Stroke Sciences Group is the research arm of our Neurovascular Service, and it is directed by Heather Fullerton, MD.

We are currently enrolling patients in studies designed at UCSF to answer specific clinical questions.

Trials that are not currently enrolling patients are listed here.

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

PI: S. Claiborne Johnston, MD, PhD and J. Donald Easton, MD

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS); University of California, San Francisco

This randomized, double-blind, multicenter clinical trial is to determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg is effective in improving survival free from major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of TIA onset in patients receiving aspirin 50-325 mg/day.

Eligibility: Must be at least 18 years of age with high-risk TIA (defined as an ABCD2 score >4) or minor ischemic stroke (with an NIHSS <3). Participants will be followed for 90 days from randomization. A total of 4,150 patients will be recruited and the trial will be completed in 2017.

Contact: Mary Farrant, 415-502-2096

More Information: http://pointtrial.org/

line

VIPS: Vascular Effects of Infection in Pediatric Stroke

PI: Heather Fullerton, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

VIPS is a multicenter cohort study of childhood stroke to test the following overall hypotheses: Infection can lead to arterial ischemic stroke (AIS) by causing vascular injury, and the resultant arteriopathy predisposes children to recurrent stroke.

Eligibility: Children must be 1 month to 18 years of age with arterial ischemic stroke.

Contact:: Katherine Sear, 415-476-4928

line

Predictors of Outcome After Subarachnoid Hemorrhage

PI: Nerissa Ko, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

To examine the clinical and genetic risk factors for functional and cognitive impairment after subarachnoid hemorrhage (SAH).

Eligibility: Must be over 18 years old and admitted to UCSF with a diagnosis of SAH and have documentd evidence of an intracranial aneurysm by by cerebral angiography, magnetic resonance angiogram, or computed tomographic angiogram.

Contact: Keiko Fukuda, 415-502-8912

line

Nitric Oxide-ergic Regulation of Human Cerebral Blood Flow (XENON)

PI: Nerissa Ko, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

To better understand how different types of neurointerventional treatment, including vasospasm treatment for aneurysmal SAH patients and angioplasty and/or stenting for cerebral arterial stenosis patients, affect cerebral blood flow. Cerebral blood flow will be measured with a radioactive tracer, Xenon, before and after treatment.

Eligibility: Patients must be over 18 with aneurismal subarachnoid hemorrhage (SAH) or cerebral arterial stenosis and were treated for vasospasm or cerebral arterial stenosis.

Contact: Keiko Fukuda, 415-502-8912

line

Familial Intracranial Aneurysm (FIA) Study

Site PI: Nerissa Ko, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

FIA is a collaborative research effort of neurologists and neurosurgeons throughout the United States, Canada, Australia, and New Zealand who are working through this study to identify possible genes and other risk factors involved in the risk of development of intracranial aneurysms.

Eligibility: Participants must have an intracerebral aneurysm(s), ruptured or unruptured. No family history is required.

Contact: Peter Buekea, 415-514-2120

line

RadART-PRO, a prospective multi-institutional study to assess the risk of radiation-induced vasculopathy and stroke as well as stroke recurrence in children with cancer who received radiation therapy to the neck and/or brain

PI: Heather Fullerton, MD, MAS/Sabine Mueller, MD, PhD

Sponsor: This study is made possible by a generous gift from the LaRoche Family.

An observational study to better understand the effect of radiation on vessels. The long-term goal is to find ways to avoid this complication among children that survived their cancer.

Eligibility: Must be < 21 years at time of radiation therapy and have received radiation to the brain and/or neck 1 year prior to enrollment for underlying diagnosis of cancer.

Contact: Katherine Sear, 415-476-4928

line

SF-NETT (part of Neurological Emergencies Treatment Trials (NETT)

PI: J. Claude Hemphill, MD, MAS

Sponsor: National Institutes of Health (NIH)

Now conducting large simple trials to reduce the burden of very acute injuries and illnesses affecting the brain, spinal cord, and peripheral nervous system. The network recognizes and seeks to explore the special narrow window of opportunity that seems to exist in treating neurologic damage from a variety of pathologies ranging from stroke to traumatic brain injury to seizures to meningitis. This network provides the basis for conducting efficient studies in these environments.

Dr. Hemphill's research program is conducted at San Francisco General Hospital. Visit an outline of his research here.

Enrollment: The NETT study of rapid interventions will be implemented by paramedics in the field, or by physicians in the Emergency Department.

line

Insulin Resistance Intervention After Stroke (IRIS)

Site PI: Anthony Kim, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of IRIS is to determine the effectiveness of pioglitazone, compared with placebo, for prevention of recurrent stroke and heart attack among non-diabetic men and women with a recent ischemic stroke or transient ischemic attack (TIA) and insulin resistance.

Eligibility: Participants must be 39 years or older; able to stand, communicate.

Contact: Peter Buekea, 415-514-2120

More information: www.iristrial.org

line

Evaluating Symptoms of Transient Ischemic Attack (TIA) with WebTIA

PI: Anthony S. Kim, MD

Sponsor: National Stroke Association

The WebTIA Project is actively recruiting subjects with symptoms of transient ischemic attack (TIA) or mini-stroke for an online research study with telephone follow-up with a neurologist.

Visit http://tia.ucsf.edu/ to enroll.

Contact: Maria Kuchherzki, 415-375-0TIA (415-375-0842)

line

The International Pediatric Stroke Study (IPSS)

Site PI: Christine Fox, MS, MAS

This is an observational study led by the Hospital for Sick Children, Toronto that was initiated in 2002 by a group of physicians and scientists from Canada, the US, and the UK interested in increasing our understanding of neonatal and childhood stroke.

Enrollment: The patient’s treating physician can make a referral. Neonates (neonate: 37 weeks gestation to 28 days of life) and older children (29 days to the 19th birthday) with a diagnosis of arterial ischemic stroke (AIS) or cerebral sinovenous thrombosis are eligible.

Contact: Katherine Sear, 415-476-4928

line

The Impact of Seizures in Infants and Children with Ischemic Stroke (SIPS)

Site PI: Christine Fox, MD

Sponsor: Pediatric Epilepsy Research Foundation

An observational study led by the Hospital for Sick Children, Toronto to better understand seizures in children who have ischemic stroke so that we can find new ways to better help these patients.

Referrals may ay be made from the patient’s treating physician or through mailed recruitment letters.

Contact: Katherine Sear, 415-476-4928

line

KP Dizziness Project

Site PI: Anthony Kim, MD, MAS

Sponsor: American Heart Associaiton

A collaborative study with the Kaiser Permanente Division of Research to better understand the risk of serious cerebrovascular and cardiovascular outcomes in patients who present to the Emergency Department with dizziness symptoms. While most patients with dizziness have a benign prognosis, for some patients, dizziness can be a harbinger of serious conditions such as stroke or a cardiac arrhythmia. Our goal is to develop tools to help ED clinician efficiently and effectively manage this common symptom.

Contact: Anthony S. Kim, 415-476-3733

line

 

The following active research projects are not enrolling patients.

Stenting vs Aggressive Medical Management for Preventing Recurrent Events in Intracranial Stenosis (SAMMPRIS)

Site PI: Sharon Poisson, MD, MAS

Sponsor: National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)

This is a multi-site, interventional study led by Medical University of South Carolina (MUSC) to study patients with 70-99% stenosis of a major intracranial artery (MCA, carotid, vertebral, basilar) and TIA or non-disabling stroke within 30 days prior to enrollment. The aim is to determine whether intensive medical therapy plus intracranial angioplasty and stenting is superior to intensive medical therapy alone for preventing: any stroke or death within 30 days after study entry, or any stroke or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, or ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up.

Contact: Sharon Poisson, 415-476-2492

line

For a list of other clinical trials in neurology at UCSF, please visit this page.

 

Quick Links
Make a Gift